{"DataElement":{"publicId":"3207916","version":"1","preferredName":"Attenuated Live Virus Vaccine Immunization Plan Ind-2","preferredDefinition":"the yes/no indicator related to the planned use of a technique used to cause an immune response by live vaccines.","longName":"3207081v1.0:2018279v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3207081","version":"1","preferredName":"Attenuated Live Virus Vaccine Immunization Plan","preferredDefinition":"information related to the planned use of a technique used to cause an immune response by live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strain.","longName":"3207079v1.0:2177451v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"3207079","version":"1","preferredName":"Attenuated Live Virus Vaccine Immunization","preferredDefinition":"Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strain:A technique used to cause an immune response that results in resistance to a specific disease, especially an infectious disease.","longName":"C1920:C15258","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Attenuated Live Virus Vaccine","conceptCode":"C1920","definition":"Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. Live-attenuated vaccines are used when a CD8+ T Cell (cellular cytotoxicity) response is desired.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunization","conceptCode":"C15258","definition":"Inoculating an individual with either killed or live agents to prevent contraction of a disease.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F2AA794-AFF0-4ACD-E040-BB89AD432A83","latestVersionIndicator":"Yes","beginDate":"2011-03-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-03-23","modifiedBy":"ONEDATA","dateModified":"2011-03-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177451","version":"1","preferredName":"Planned","preferredDefinition":"Planned; devised, contrived, or formed in design.","longName":"Planned","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Plan","conceptCode":"C25619","definition":"To devise, contrive, or form in design.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-525D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F2AA794-AFFE-4ACD-E040-BB89AD432A83","latestVersionIndicator":"Yes","beginDate":"2011-03-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-03-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"3207081v1.0:2018279v1.0","type":"USED_BY","context":"CITN"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"LIVE_VIRUS_VACCINE_PLAN","type":"Context Short Name","context":"NRG"}],"ReferenceDocuments":[{"name":"Planned immunization with att","type":"Preferred Question Text","description":"Planned immunization with attenuated live vaccines <=7 days prior to registration or during study period","url":null,"context":"CTEP"},{"name":"CRF Text 1","type":"Alternate Question Text","description":"Has had live vaccines within 30 days before the first dose of trial treatment and while participating in the trial","url":null,"context":"CTEP"},{"name":"CRF Text 2","type":"Alternate Question Text","description":"Has received a live vaccine within 30 days prior to the first dose of trial treatment","url":null,"context":"CTEP"},{"name":"CRF Text 3","type":"Alternate Question Text","description":"Is it anticipated that the patient will require a live, attenuated vaccine during the study (excluding influenza vaccination that should be given during the influenza season only)","url":null,"context":"CTEP"},{"name":"CRF Text 4","type":"Alternate Question Text","description":"Is it anticipated that the patient will require a live, attenuated vaccine during the study and up to 5 months after the last dose of atezolizumab (excluding influenza vaccination that should be given during the influenza season only)","url":null,"context":"CTEP"},{"name":"CRF Text 5","type":"Alternate Question Text","description":"Is it anticipated that the patient will require a live, attenuated vaccine during the study and up to 5 months after the last dose of atezolizumab?","url":null,"context":"CTEP"},{"name":"CRF Text 6","type":"Alternate Question Text","description":"Has the patient received a live vaccination within 28 days before randomization?","url":null,"context":"CTEP"},{"name":"CITN-2","type":"Alternate Question Text","description":"Has had live vaccines within 30 days before the first dose of trial retreatment and while participating in the trial.","url":null,"context":"CITN"},{"name":"CRF Text 7","type":"Alternate Question Text","description":"Has the patient received a live, attenuated vaccine within 4 weeks of randomization?","url":null,"context":"CTEP"},{"name":"NRG CRF_TEXT1","type":"Alternate Question Text","description":"Has the patient received administration of a live, attenuated vaccine within 4 weeks prior to registration or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab?","url":null,"context":"NRG"},{"name":"NRG_CRF Text 2","type":"Alternate Question Text","description":"Has the patient received administration of a live, attenuated vaccine within 4 weeks prior to registration or anticipation that such a live, attenuated vaccine will be required during the study and for patients receiving atezolizumab, up to 5 months after the last dose of atezolizumab?","url":null,"context":"NRG"},{"name":"NRG_CRF Text 3","type":"Alternate Question Text","description":"Has the patient received administration of a live, attenuated vaccine within 3 weeks prior to registration or anticipation that such a live, attenuated vaccine will be required during receipt of study treatment and up to 5 months after the last dose of study drug?","url":null,"context":"NRG"},{"name":"NRG_CRF Text 4","type":"Alternate Question Text","description":"Has the patient received administration of a live, attenuated vaccine within 4 weeks prior to registration or anticipation that such a live, attenuated vaccine will be required during receipt of study treatment and up to 5 months after the last dose of study drug?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Is it anticipated that the patient will require a live, attenuated vaccine during the study?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_1","type":"Alternate Question Text","description":"Has the patient received a live, attenuated vaccine within 4 weeks prior to study entry?","url":null,"context":"NRG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Did the patient receive live vaccine within 30 days prior to planned Day 1 of protocol therapy (e.g., measles, mumps, rubella, varicella, yellow fever, rabies, BCG, oral polio vaccine, and oral typhoid)?","url":null,"context":"COG"},{"name":"COG CRF Text 8","type":"Alternate Question Text","description":"Has patient received immunizations with attenuated live vaccines within 28 days of study entry?","url":null,"context":"COG"}],"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9F2AFC1A-269C-98BF-E040-BB89AD4367EA","latestVersionIndicator":"Yes","beginDate":"2011-03-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-03-23","modifiedBy":"KUMMEROA","dateModified":"2023-03-28","changeDescription":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"2023.3.28 AQT added per ticket request CADSR0002221. ak 2023.3.17 AQT added per ticket request CADSR0002164. ak","unresolvedIssues":null,"deletedIndicator":"No"}}